Mirum Pharmaceuticals (NASDAQ:MIRM) Director Acquires $49,290.00 in Stock

Mirum Pharmaceuticals (NASDAQ:MIRM) Director Laurent Fischer purchased 4,650 shares of the business’s stock in a transaction on Tuesday, September 10th. The shares were bought at an average price of $10.60 per share, for a total transaction of $49,290.00.

Shares of NASDAQ:MIRM traded up $0.14 on Friday, hitting $10.02. 10,834 shares of the company’s stock were exchanged, compared to its average volume of 42,818. The stock’s 50-day moving average is $13.00. Mirum Pharmaceuticals has a 1-year low of $9.25 and a 1-year high of $15.50.

Mirum Pharmaceuticals (NASDAQ:MIRM) last released its quarterly earnings data on Wednesday, August 28th. The company reported ($2.29) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.46) by ($1.83). As a group, research analysts forecast that Mirum Pharmaceuticals will post -3.3 EPS for the current fiscal year.



Several equities research analysts have weighed in on MIRM shares. Roth Capital started coverage on Mirum Pharmaceuticals in a report on Monday, August 12th. They set a “buy” rating and a $33.00 price target on the stock. Guggenheim started coverage on Mirum Pharmaceuticals in a report on Monday, August 12th. They set a “buy” rating and a $18.00 price target on the stock. Raymond James started coverage on Mirum Pharmaceuticals in a report on Monday, August 12th. They set an “outperform” rating and a $28.00 price target on the stock. Citigroup started coverage on Mirum Pharmaceuticals in a report on Monday, August 12th. They set a “buy” rating and a $21.00 price target on the stock. Finally, Evercore ISI started coverage on Mirum Pharmaceuticals in a report on Monday, August 12th. They set an “outperform” rating and a $25.00 price target on the stock. Five equities research analysts have rated the stock with a buy rating, The stock has an average rating of “Buy” and an average target price of $25.00.

Mirum Pharmaceuticals Company Profile

Mirum Pharmaceuticals, Inc, a clinical-stage therapeutics company, develops and produces therapies for patients with cholestatic liver diseases with a focus on rare pediatric conditions. The company's lead product candidate is maralixibat, a Phase 3-ready investigational oral drug with indications, including Alagille syndrome (ALGS) and progressive familial intrahepatic cholestasis (PFIC).

Further Reading: After-Hours Trading

Receive News & Ratings for Mirum Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Mirum Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.